|
EP4219560A3
(en)
|
2010-02-18 |
2023-08-23 |
The Regents of The University of California |
Integrin alpha v beta 8 neutralizing antibody
|
|
JP2014510080A
(ja)
*
|
2011-03-09 |
2014-04-24 |
セントローズ， エルエルシー |
細胞外標的化薬物複合体
|
|
WO2013023162A2
(en)
*
|
2011-08-10 |
2013-02-14 |
Genus Oncology, Llc |
Anti-muc1 antibodies for cancer diagnostics
|
|
SG2014014237A
(en)
|
2011-08-17 |
2014-07-30 |
Univ California |
Antibodies that bind integrin alpha-v beta-8
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN102786595B
(zh)
*
|
2012-08-03 |
2014-04-23 |
无锡傲锐东源生物科技有限公司 |
抗cd5蛋白单克隆抗体及其用途
|
|
CN107880126B
(zh)
|
2012-12-21 |
2021-03-30 |
西雅图基因公司 |
抗ntb-a抗体及相关组合物和方法
|
|
JP6441232B2
(ja)
*
|
2012-12-27 |
2018-12-19 |
サノフイＳａｎｏｆｉ |
抗ｌａｍｐ１抗体および抗体薬物コンジュゲート、ならびにその使用
|
|
HRP20191865T1
(hr)
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CA2939572A1
(en)
*
|
2014-02-19 |
2015-08-27 |
Jody Berry |
Marburg monoclonal antibodies
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
US10786549B2
(en)
|
2015-04-23 |
2020-09-29 |
Baylor College Of Medicine |
CD5 chimeric antigen receptor for adoptive T cell therapy
|
|
US11369663B2
(en)
*
|
2016-06-07 |
2022-06-28 |
Washington University |
Detection of CD5 and methods and compositions for modulating CD5
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
WO2018017864A2
(en)
*
|
2016-07-20 |
2018-01-25 |
Oncomed Pharmaceuticals, Inc. |
Pvrig-binding agents and uses thereof
|
|
CN109923126B
(zh)
*
|
2016-09-16 |
2022-06-03 |
上海复宏汉霖生物技术股份有限公司 |
抗-pd-1抗体
|
|
US20180128545A1
(en)
|
2016-11-08 |
2018-05-10 |
Berry Metal Company |
Modular furnace cooling wall
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
KR20200094181A
(ko)
|
2017-11-29 |
2020-08-06 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd5+ 세포를 고갈시키기 위한 조성물 및 방법
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
IL316074A
(en)
*
|
2018-04-18 |
2024-12-01 |
Biomadison Inc |
Compounds for determining vaccine potency
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
CN113454117B
(zh)
|
2018-12-19 |
2025-07-04 |
宾夕法尼亚大学董事会 |
Cd2/5/7敲除抗-cd2/5/7嵌合抗原受体t细胞针对t细胞淋巴瘤和白血病的用途
|
|
KR20210137485A
(ko)
|
2019-04-05 |
2021-11-17 |
아카데미아 시니카 |
시알리다제-내성 당류 및 이의 제조 및 사용 방법
|
|
WO2020216947A1
(en)
|
2019-04-24 |
2020-10-29 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
KR20220097875A
(ko)
|
2019-09-03 |
2022-07-08 |
마이얼로이드 테라퓨틱스, 인크. |
게놈 통합을 위한 방법 및 조성물
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
IL298035A
(en)
|
2020-05-08 |
2023-01-01 |
Academia Sinica |
Chimeric influenza vaccines
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
WO2021231982A1
(en)
*
|
2020-05-14 |
2021-11-18 |
City Of Hope |
Smc1a antibodies and uses thereof
|
|
EP3915641A1
(en)
*
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
|
JP2023538108A
(ja)
*
|
2020-08-21 |
2023-09-06 |
シティ・オブ・ホープ |
抗ｃｄ５抗体組成物及びその使用
|
|
WO2022056459A1
(en)
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Compositions and methods for cd5 modification
|
|
MX2023005201A
(es)
|
2020-11-04 |
2023-06-28 |
Myeloid Therapeutics Inc |
Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
|
|
WO2022099090A1
(en)
*
|
2020-11-06 |
2022-05-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind tgfbrii
|
|
US20250179172A1
(en)
*
|
2020-12-17 |
2025-06-05 |
Hainan Simcere Zaiming Pharmaceutical Co., Ltd. |
Cd5 antibody and use thereof
|
|
US20240050568A1
(en)
*
|
2021-01-12 |
2024-02-15 |
Nanjing IASO Biotechnology Co., Ltd. |
Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof
|
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
EP4164687A4
(en)
|
2021-04-12 |
2024-08-14 |
Academia Sinica |
IMPROVED CORONAVIRUS VACCINE
|
|
JP7716500B2
(ja)
*
|
2021-04-29 |
2025-07-31 |
コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー |
新規な抗ｃｄ５キメラ抗原受容体及びそれを発現する免疫細胞
|
|
EP4337268A4
(en)
|
2021-05-11 |
2025-06-04 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
CN113105547B
(zh)
*
|
2021-05-18 |
2022-04-08 |
福州迈新生物技术开发有限公司 |
抗cd5蛋白单克隆抗体及其细胞株、制备方法和应用
|
|
TW202334429A
(zh)
|
2021-10-01 |
2023-09-01 |
中央研究院 |
Sars-cov-2棘蛋白特異性抗體及其用途
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
US12077597B2
(en)
|
2021-11-24 |
2024-09-03 |
International-Drug-Development-Biotech |
Anti-CD5 antibodies and methods of use thereof
|
|
WO2023129928A2
(en)
*
|
2021-12-27 |
2023-07-06 |
Academia Sinica |
Antibody specific to spike protein of sars-cov-2 and uses thereof
|
|
WO2024039683A1
(en)
*
|
2022-08-15 |
2024-02-22 |
Myeloid Therapeutics, Inc. |
Compositions and methods for conditioning patients for cell therapy
|
|
EP4572772A1
(en)
|
2022-08-17 |
2025-06-25 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
IL319558A
(en)
|
2023-04-08 |
2025-05-01 |
Rock Biomedical Inc |
Methods and compositions for targeted delivery using polymersomes
|
|
US12311033B2
(en)
|
2023-05-31 |
2025-05-27 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2024258967A1
(en)
*
|
2023-06-13 |
2024-12-19 |
Synthis Therapeutics, Inc. |
Anti-cd5 antibodies and their uses
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025149667A1
(en)
|
2024-01-12 |
2025-07-17 |
Pheon Therapeutics Ltd |
Antibody drug conjugates and uses thereof
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|